A drug originally identified by Cain Lab researchers approved by EU for partial-onset seizures in Tuberous Sclerosis patients

A drug initially discovered by the researchers in the Gordon and Mary Cain Foundation for Pediatric Neurology Research at Texas Children’s Hospital to be effective in treating refractory seizures commonly seen in tuberous sclerosis patients is now approved for use in Europe.

New study reveals how repeated early-life seizures alter microanatomy of neurons

A recent study published in eNeuro from the laboratory of Dr. John Swann, director of the Gordon and Mary Cain Pediatric Neurology Research Foundation Laboratories at Texas Children’s Hospital shows how frequent seizures alter the microanatomy of neurons in the brain and that the activity of a specific enzyme may contribute to the cognitive and behavioral deficits observed in children with epileptic encephalopathies.

CDC finds an increase in epilepsy among Americans

“Number of Americans with active epilepsy is increasing,” concludes a national and state-specific study that was published last week in the Center for Disease Control and Prevention (CDC)’s Morbidity and Mortality Report.

Epilepsy, a common neurological disorder characterized by repeated seizures that can involve temporary loss of consciousness, altered or rapid eye movements, involuntary muscular jerks or twitching and other symptoms.

Cannabidiol: A therapeutic option for Lennox-Gastaut syndrome?

What is Lennox-Gastaut syndrome?

Lennox-Gastaut syndrome (LGS) is a form of severe childhood epilepsy that firsts manifests in children between the ages of 2 to 5 years and often persists into adulthood. Children with this syndrome have life-long behavioral, psychological and cognitive problems. There is also an increased risk of death due to uncontrolled seizures and/ injuries from sudden drop attacks.